Sarepta Therapeutics (SRPT) Gross Profit (2017 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Gross Profit of $622.0 million for Q1 2026, up 14801.84% year-over-year from N/an in Q1 2025, and up 1306.49% quarter-over-quarter from $44.2 million in Q4 2025.
Sarepta Therapeutics (SRPT) Gross Profit (2017 - 2026) Analysis & Trends
Sarepta Therapeutics' Gross Profit history runs 10 years deep, the most recent figure standing at $622.0 million for Q1 2026.
- In Q1 2026, Gross Profit rose 14801.84% year-over-year to $622.0 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 12.97% YoY), while the FY2025 annual figure was $1.0 billion, down 35.26% from the prior year.
- Gross Profit for Q1 2026 stood at $622.0 million, up from $44.2 million in the prior quarter.
- The five-year high for Gross Profit was $1.0 billion in Q4 2023, with the low at -$4.2 million in Q1 2025.
- The 5-year median for Gross Profit is $272.3 million (2023), against an average of $355.2 million.
- The sharpest annual moves came in 2022 and 2025: Gross Profit jumped 20154.48% in 2022, then slumped 101.17% in 2025.
- Sarepta Therapeutics' Gross Profit stood at $835.5 million in 2022, then grew by 23.76% to $1.0 billion in 2023, then slumped by 49.12% to $526.1 million in 2024, then slumped by 91.59% to $44.2 million in 2025, then soared by 1306.49% to $622.0 million in 2026.
- Business Quant data shows SRPT's Gross Profit at $622.0 million in Q1 2026, $44.2 million in Q4 2025, and $248.6 million in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|